![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 16, 2010 9:52:38 AM
FDA pushes off ticagrelor decision for three more months
Written by Editorial Staff
September 16, 2010
The FDA has extended the time to complete its review of the new drug application (NDA) for ticagrelor (Brilinta, AstraZeneca) from Sept. 16 to Dec. 16.
The London-based AstraZeneca said it will “continue to work closely with the FDA to support the review of the ticagrelor NDA.”
Ticagrelor is currently under regulatory review in nine additional global territories, including the European Union, Canada and Brazil.
Ticagrelor (Brilinta/Brilique), an investigational oral antiplatelet treatment for acute coronary syndromes, is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines.
Ticagrelor is a reversibly-binding oral ADP receptor antagonist. The PLATO (PLATelet inhibition and patient Outcomes) study found that ticagrelor decreased incidences of cardiovascular death, MI and stroke when compared with clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis)
http://www.cardiovascularbusiness.com/index.php?option=com_articles&view=article&id=24134&division=cvb
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM